Navigation Links
Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Date:10/21/2008

or responses needed to proceed to Stage B. In Stage B, the trial is being expanded to include an additional 31 patients, for a total of 46 patients overall. Secondary objectives of the study include assessing time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 182,460 U.S. women will be diagnosed with breast cancer in 2008 and 40,480 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in two separate Phase II combination therapy trials for the treatment of advanced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ('/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Ale Gicqueau, Founder and President of ... Affairs at Align Technology, on “ Conducting Postmarket Registries ... 2015 Global Conference and Exhibition on April 25th through ... During the poster presentation, Ale Gicqueau and Victor Chen ... Postmarket Registry, the requirements and resources to conduct the ...
(Date:3/25/2015)... TORONTO , March 25, 2015 /PRNewswire/ - SQI Diagnostics ... announced that, as a result of recent discussions with ... common shares of the Company, after dealing with certain ... and special meeting of shareholders on March 26, 2015 ... that the election of directors will take place when ...
(Date:3/25/2015)... 25, 2015 Laboratory workers can ... and Analytical Balances to get best-performing features while ... weighing balances from the trusted brand include: , ... increase your efficiency by providing a large weighing ... Weighing modes include parts counting, percent weighing, checkweighing, ...
(Date:3/25/2015)... 2015  Point-of-Care Partners, a leading health information ... launched the ePrescribing State Law Capsule -- a ... regulatory requirements in all 50 states and DC.  ... to change rapidly, so we have evolved our ... ultimately patients, need," said Tony Schueth , ...
Breaking Biology Technology:Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Point-of-Care Partners Launches the ePrescribing State Law Capsule 2
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext ... identifies, develops and commercializes differentiated products for ... received clearance from Canadian regulatory authorities to ... for nimotuzumab, its EGFR-targeting antibody, in combination ...
... 5 LightLab Imaging Inc. today,announced several ... year that are,the culmination of sustained clinical ... advances significantly increase the Company,s leadership,position in ... OCT is a new,high-resolution, high-speed imaging modality ...
... Wyeth (NYSE: WYE ) announced today ... CEOs Unscripted Conference on Wednesday, January 7, 2009 at ... be Bernard Poussot, Chairman, President and Chief Executive Officer.Wyeth,s ... www.wyeth.com and available for replay following the conference.Wyeth ...
Cached Biology Technology:YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7LightLab Imaging Leads Global Advancement of Intracoronary Imaging 2LightLab Imaging Leads Global Advancement of Intracoronary Imaging 3Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference 2
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report to ... for Hand Geometry in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and ...
(Date:3/19/2015)... OXFORD, Conn. , March 19, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce market, ... featured in a news clip that aired this week on ... http://www.myfoxdc.com/ ) . In a segment "The Next ... smart wallet ,a new way to pay, and ,a really ...
(Date:3/17/2015)... DIEGO , March 17, 2015 ... emotion analytics software, today announced general availability of ... web service for the analysis of facial expressions. ... experience advertising, media content, products and services. It ... attention, engagement and sentiment - as derived from ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... Registration is now open for Disease Models & ... Mechanisms. This one-day Symposium will ... and disease processes at the cellular and whole-organism ... be used to address this issue. It is ...
... flower, created by the union of two foreign plant species, ... Genetic changes in this attractive yellow-flowered hybrid have allowed it to ... new species that has originated in the wild in the last ... to have originated in this way, yet only a handful of ...
... A San Francisco State University biologist has released the ... bee populations and has found low numbers of bees in ... habitat loss is one of the primary reasons for sharp ... Now the researcher plans to add to her data ...
Cached Biology News:Rare glimpse into the origin of species 2SF State researcher releases first results from nationwide bee count 2SF State researcher releases first results from nationwide bee count 3
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
Biotin anti-human CD164...
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
... SeeDNA co-precipitant, 250 ul ... color ensures easy pellet ... acid recovery.Chemically inert, compatible ... applications.Simple 5-minute protocol. Category: ...
Biology Products: